DURECT Corporation (DRRX)
USD 0.6
(3.1%)
USD 0.6
(3.1%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.54 Million USD | -55.67% |
| 2022 | 19.28 Million USD | 37.96% |
| 2021 | 13.97 Million USD | -53.58% |
| 2020 | 30.11 Million USD | 1.85% |
| 2019 | 29.56 Million USD | 59.25% |
| 2018 | 18.56 Million USD | -62.25% |
| 2017 | 49.17 Million USD | 250.59% |
| 2016 | 14.02 Million USD | -26.66% |
| 2015 | 19.12 Million USD | -1.43% |
| 2014 | 19.4 Million USD | 26.59% |
| 2013 | 15.32 Million USD | -71.12% |
| 2012 | 53.07 Million USD | 58.48% |
| 2011 | 33.48 Million USD | 6.0% |
| 2010 | 31.59 Million USD | 30.04% |
| 2009 | 24.29 Million USD | -6.41% |
| 2008 | 25.95 Million USD | -15.38% |
| 2007 | 30.67 Million USD | 40.11% |
| 2006 | 21.89 Million USD | -23.37% |
| 2005 | 28.57 Million USD | 106.24% |
| 2004 | 13.85 Million USD | 17.05% |
| 2003 | 11.83 Million USD | 64.72% |
| 2002 | 7.18 Million USD | 10.13% |
| 2001 | 6.52 Million USD | 106.78% |
| 2000 | 3.15 Million USD | 3568.6% |
| 1999 | 86 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.82 Million USD | -31.55% |
| 2024 Q2 | 2.17 Million USD | 18.83% |
| 2023 Q2 | 2.08 Million USD | 1.31% |
| 2023 Q1 | 2.05 Million USD | -38.04% |
| 2023 Q3 | 1.74 Million USD | -16.19% |
| 2023 Q4 | 2.66 Million USD | 53.04% |
| 2023 FY | 8.54 Million USD | -55.67% |
| 2022 Q2 | 2.07 Million USD | 8.41% |
| 2022 FY | 19.28 Million USD | 37.96% |
| 2022 Q3 | 11.97 Million USD | 476.93% |
| 2022 Q4 | 3.31 Million USD | -72.32% |
| 2022 Q1 | 1.91 Million USD | -73.76% |
| 2021 Q2 | 2.3 Million USD | 4.11% |
| 2021 Q4 | 7.29 Million USD | 237.04% |
| 2021 Q1 | 2.21 Million USD | 0.23% |
| 2021 FY | 13.97 Million USD | -53.58% |
| 2021 Q3 | 2.16 Million USD | -5.99% |
| 2020 Q3 | 2.68 Million USD | -89.62% |
| 2020 Q4 | 2.2 Million USD | -17.74% |
| 2020 Q1 | 2.77 Million USD | -74.03% |
| 2020 FY | 30.11 Million USD | 1.85% |
| 2020 Q2 | 25.84 Million USD | 831.32% |
| 2019 Q1 | 4.13 Million USD | 13.9% |
| 2019 Q3 | 10.76 Million USD | 170.09% |
| 2019 Q2 | 3.98 Million USD | -3.53% |
| 2019 FY | 29.56 Million USD | 59.25% |
| 2019 Q4 | 10.68 Million USD | -0.72% |
| 2018 Q4 | 3.62 Million USD | -54.87% |
| 2018 FY | 18.56 Million USD | -62.25% |
| 2018 Q3 | 8.03 Million USD | 135.45% |
| 2018 Q2 | 3.41 Million USD | -2.15% |
| 2018 Q1 | 3.48 Million USD | -82.15% |
| 2017 Q4 | 19.53 Million USD | -5.82% |
| 2017 FY | 49.17 Million USD | 250.59% |
| 2017 Q1 | 4.56 Million USD | 29.85% |
| 2017 Q2 | 4.31 Million USD | -5.43% |
| 2017 Q3 | 20.74 Million USD | 380.34% |
| 2016 Q4 | 3.51 Million USD | -6.04% |
| 2016 Q1 | 3.6 Million USD | -30.17% |
| 2016 Q2 | 3.15 Million USD | -12.5% |
| 2016 Q3 | 3.74 Million USD | 18.56% |
| 2016 FY | 14.02 Million USD | -26.66% |
| 2015 Q4 | 5.16 Million USD | 8.94% |
| 2015 Q3 | 4.74 Million USD | 6.8% |
| 2015 Q2 | 4.44 Million USD | -6.96% |
| 2015 Q1 | 4.77 Million USD | 11.81% |
| 2015 FY | 19.12 Million USD | -1.43% |
| 2014 Q3 | 4.25 Million USD | -7.05% |
| 2014 FY | 19.4 Million USD | 26.59% |
| 2014 Q1 | 6.29 Million USD | 46.72% |
| 2014 Q4 | 4.26 Million USD | 0.26% |
| 2014 Q2 | 4.58 Million USD | -27.2% |
| 2013 Q4 | 4.28 Million USD | 44.61% |
| 2013 Q3 | 2.96 Million USD | -24.3% |
| 2013 Q2 | 3.91 Million USD | -5.66% |
| 2013 Q1 | 4.15 Million USD | 27.31% |
| 2013 FY | 15.32 Million USD | -71.12% |
| 2012 FY | 53.07 Million USD | 58.48% |
| 2012 Q1 | 41.18 Million USD | 360.94% |
| 2012 Q2 | 4.79 Million USD | -88.35% |
| 2012 Q3 | 3.82 Million USD | -20.18% |
| 2012 Q4 | 3.26 Million USD | -14.79% |
| 2011 Q3 | 8.11 Million USD | 3.6% |
| 2011 FY | 33.48 Million USD | 6.0% |
| 2011 Q4 | 8.93 Million USD | 10.1% |
| 2011 Q1 | 8.6 Million USD | 1.27% |
| 2011 Q2 | 7.83 Million USD | -8.96% |
| 2010 Q4 | 8.49 Million USD | 4.68% |
| 2010 Q2 | 7.31 Million USD | -4.6% |
| 2010 Q3 | 8.11 Million USD | 10.98% |
| 2010 Q1 | 7.66 Million USD | 57.15% |
| 2010 FY | 31.59 Million USD | 30.04% |
| 2009 Q2 | 4.87 Million USD | -20.83% |
| 2009 Q3 | 8.37 Million USD | 71.79% |
| 2009 Q4 | 4.87 Million USD | -41.78% |
| 2009 FY | 24.29 Million USD | -6.41% |
| 2009 Q1 | 6.16 Million USD | -20.27% |
| 2008 Q2 | 6.3 Million USD | -2.1% |
| 2008 Q4 | 7.72 Million USD | 16.46% |
| 2008 Q3 | 6.63 Million USD | 5.25% |
| 2008 Q1 | 6.43 Million USD | -2.23% |
| 2008 FY | 25.95 Million USD | -15.38% |
| 2007 Q4 | 6.58 Million USD | 33.52% |
| 2007 Q3 | 4.93 Million USD | -63.28% |
| 2007 Q1 | 5.72 Million USD | 5.24% |
| 2007 Q2 | 13.43 Million USD | 134.58% |
| 2007 FY | 30.67 Million USD | 40.11% |
| 2006 FY | 21.89 Million USD | -23.37% |
| 2006 Q1 | 5.21 Million USD | -9.78% |
| 2006 Q2 | 6.1 Million USD | 17.21% |
| 2006 Q3 | 5.13 Million USD | -15.95% |
| 2006 Q4 | 5.44 Million USD | 5.98% |
| 2005 Q4 | 5.77 Million USD | -33.01% |
| 2005 Q2 | 8.81 Million USD | 64.72% |
| 2005 FY | 28.57 Million USD | 106.24% |
| 2005 Q1 | 5.35 Million USD | 33.08% |
| 2005 Q3 | 8.62 Million USD | -2.23% |
| 2004 FY | 13.85 Million USD | 17.05% |
| 2004 Q3 | 3.36 Million USD | 9.25% |
| 2004 Q1 | 3.38 Million USD | 9.05% |
| 2004 Q4 | 4.02 Million USD | 19.55% |
| 2004 Q2 | 3.08 Million USD | -9.01% |
| 2003 Q1 | 2.58 Million USD | 28.66% |
| 2003 FY | 11.83 Million USD | 64.72% |
| 2003 Q4 | 3.1 Million USD | 5.22% |
| 2003 Q3 | 2.95 Million USD | -7.81% |
| 2003 Q2 | 3.2 Million USD | 23.98% |
| 2002 Q3 | 1.78 Million USD | 0.62% |
| 2002 Q2 | 1.77 Million USD | 9.11% |
| 2002 Q1 | 1.62 Million USD | 1.75% |
| 2002 FY | 7.18 Million USD | 10.13% |
| 2002 Q4 | 2 Million USD | 12.51% |
| 2001 Q4 | 1.59 Million USD | -13.31% |
| 2001 Q3 | 1.84 Million USD | 9.13% |
| 2001 Q2 | 1.68 Million USD | 20.59% |
| 2001 Q1 | 1.39 Million USD | 43.78% |
| 2001 FY | 6.52 Million USD | 106.78% |
| 2000 Q3 | 1.1 Million USD | 103.51% |
| 2000 Q1 | 541 Thousand USD | 0.0% |
| 2000 FY | 3.15 Million USD | 3568.6% |
| 2000 Q2 | 541 Thousand USD | 0.0% |
| 2000 Q4 | 973 Thousand USD | -11.63% |
| 1999 FY | 86 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 98.244% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 83.101% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 98.492% |
| Cosmos Health Inc. | 53.37 Million USD | 83.986% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -694.125% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 92.652% |
| Cronos Group Inc. | 88.84 Million USD | 90.378% |
| Incannex Healthcare Limited | 12 Thousand USD | -71133.333% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 93.335% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 64.521% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 64.521% |
| SCYNEXIS, Inc. | 140.14 Million USD | 93.9% |
| Safety Shot Inc | 202.67 Thousand USD | -4117.694% |
| Theratechnologies Inc. | 81.76 Million USD | 89.546% |
| Alpha Teknova, Inc. | 36.68 Million USD | 76.698% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 73.543% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 98.734% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 32.878% |
| Dynavax Technologies Corporation | 232.28 Million USD | 96.32% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 98.069% |
| Radius Health, Inc. | 2.88 Billion USD | 99.703% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -343.247% |
| Alvotech | 91.43 Million USD | 90.651% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 98.159% |
| SIGA Technologies, Inc. | 139.91 Million USD | 93.891% |
| Shineco, Inc. | 9.8 Million USD | 12.792% |
| Silver Spike Investment Corp. | 11.72 Million USD | 27.078% |
| Journey Medical Corporation | 79.18 Million USD | 89.204% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -46.813% |
| Embecta Corp. | 1.12 Billion USD | 99.237% |
| Harrow Health, Inc. | 130.19 Million USD | 93.434% |
| Procaps Group, S.A. | 409.92 Million USD | 97.915% |
| Biofrontera Inc. | 34.07 Million USD | 74.911% |
| PainReform Ltd. | - USD | -Infinity% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 98.593% |
| OptiNose, Inc. | 70.98 Million USD | 87.958% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -31.242% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 98.027% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 78.388% |
| ProPhase Labs, Inc. | 44.38 Million USD | 80.741% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 99.16% |
| Procaps Group S.A. | 409.92 Million USD | 97.915% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -556.528% |
| Viatris Inc. | 15.42 Billion USD | 99.945% |
| Rockwell Medical, Inc. | 83.61 Million USD | 89.777% |
| Aytu BioPharma, Inc. | 81 Million USD | 89.447% |
| Tilray Brands, Inc. | 788.94 Million USD | 98.917% |
| PetIQ, Inc. | 1.1 Billion USD | 99.224% |
| Talphera, Inc. | 651 Thousand USD | -1213.057% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.547% |
| Alimera Sciences, Inc. | 80.75 Million USD | 89.415% |
| Assertio Holdings, Inc. | 152.06 Million USD | 94.379% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | 69.431% |
| Hempacco Co., Inc. | 4.04 Million USD | -111.289% |
| Alvotech | 91.43 Million USD | 90.651% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 99.341% |
| Kamada Ltd. | 144.75 Million USD | 94.095% |
| Currenc Group, Inc. | 53.25 Million USD | 83.949% |
| Indivior PLC | 1.09 Billion USD | 99.218% |
| Evoke Pharma, Inc. | 5.18 Million USD | -64.999% |
| Flora Growth Corp. | 76.07 Million USD | 88.763% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -694.125% |
| Evolus, Inc. | 202.08 Million USD | 95.77% |
| HUTCHMED (China) Limited | 837.99 Million USD | 98.98% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 98.673% |
| Akanda Corp. | 2.16 Million USD | -295.731% |